

OFFICE
MAR 10 2003
PATENT & TRADEMARK

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10287-051001	Application No. 09/536,087
	Applicant Michael J. Detmar et al.		
	Filing Date March 24, 2000	Group Art Unit 1642	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
my	AA	4,404,199	9/13/83	Bonaldi et al.			
	AB	4,487,833	1211/84	Donahoe et al.			
	AC	4,510,131	4/9/85	Donahoe et al.			
	AD	4,753,794	6/18/88	Donahoe et al.			
	AE	4,792,601	12/20/88	Donahoe et al.			
	AF	5,011,687	4/30/91	Donahoe et al.			
	AG	5,047,336	9/10/91	Cate et al.			
	AH	5,198,420	3/30/93	Donahoe et al.			
	AI	5,661,126	8/26/97	Donahoe et al.			
	AJ	5,204,055	420/93	Sachs et al.			
	AK	5,759,830	6/2/98 -	Vacanti, et al.,			
	AL	5,709,854	01/20/98	Griffith-Cant et al.			

RECEIVED
MAR 12 2003
FBI CENTER 1600/2900

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
my	AM	WO 94/00133	1/06/94	WIPO			Yes	No
	AN	WO 94/25080	11/10/94	WIPO				
	AO	WO 93/17669	09/16/93	WIPO				
	AP	WO 96/40002	12/19/96	WIPO				
	AQ							

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
my	AR	Gilbert et al., "Cell transportation of genetically altered cells on biodegradable polymer scaffolds in syngeneic rats" Transplantation, vol. 56,2 August 1998,pgs 423-427.
↓	AS	Qin et al., "Interferon-beta gene therapy inhibits tumor formation and causes regression of established hanors in irtarnute-deficient mice" Proc. Nad Aced. Sci. USA, vol. 95, November 1998, pgs 14411-14416.

Examiner Signature <i>March 4</i>	Date Considered 11-13-03
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

PTO
MAR 10 2003
PATENT & TRADEMARK OFFICE


Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 10287-051001	Application No. 09/536,087
	Applicant Michael J. Detmar et al.			
	Filing Date March 24, 2000		Group Art Unit 1642	

TECH CENTER 1600/2900
MAR 12 2003

RECEIVED

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
my	AT	Cao et al., "Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases" J. Clin. Invest. vol. 101, no. 5, 5 March 1998, pp 1055-1063.
	AU	Vacanti & Langer, "Tissue engineering: the design and fabrication of living replacement devices for surgical reconstruction and transplantation" The Lancet, vol. 34, no. Supp424 July 1999, pgs 32-34.
	AV	Stephen et al., "Tissue-engineered cells producing complex recombinant proteins inhibit ovarian cancer in vivo" Proc. Natl. Acad. Sci. USA, vol. 98, no. 6, 13 March 2001, pgs 3214-3219.
	AW	Detmar et al. "Overexpression of Vascular Permeability Factor/Vascular Endothelial Growth Factor and its Receptors in Psoriasis" J. Exp. Med. Vol. 180: 1141-1146. <i>sept. 1994 my</i>
	AX	Jackson et al. (1997) "The codependence of angiogenesis and chronic inflammation" 11(6):457-464.
	AY	Lunge-Asachenfeldt et al. (2002) "Increased and prolonged inflammation and angiogenesis in delayed-type hypersensitivity reactions elicited in the skin of thymospondin-2-deficient mice" Blood 99(2) 538-545.
	AZ	Martin, P., Science 276, 671-674 (1997)
	AAA	O'Reilly, M., et al., Nature Med. 2, 689-692 (1996)
	ABB	Budzik et al. (1983) "Mullerian Inhibiting Substance Fractionation by dye affinity Chromatography" Cell, vol. 34: 304-314.
	ACC	Boveri et al. (1993) "Transfection of the Mullerian Inhibiting Substance gene inhibits local and metastatic tumor growth" International Journal of Oncology 2:135-143
	ADD	Bogden et al. (1979) "Growth of Human Tumor Xenografts Implanted under the Renal Capsule of Normal Immature Competent Mice" Expl Cell Biol. 47: 281-293
	AEE	Chin et al. (1991) "Human Mullerian Inhibiting Substance Inhibits Tumor Growth in Vitro and in Vivo" Cancer Research 51: 2101-2106.
	AFF	Cate et al. (1986) "Development of Mullerian Inhibiting Substance as an Anti-cancer Drug" Cold Spring Harbor Symposia on Quantitative Biology, Volume LI: 641-647.
	AGG	Cate et al. (1986) "Isolation of the Bovine and Human Genes for Mullerian Inhibiting Substance and Expression of the Human Gene in Animal Cells" Cell, vol 45: 685-698
	AHH	Donahoe et al. (1979) "Mullerian Duct Regression in the Embryo Correlated with Cytotoxic Activity Against Human Ovarian Cancer" Science, vol. 205 913-915
	AII	Donahoe et al (1977) "A graded organ culture assay for the detection of Mullerian Inhibiting Substance" Journal of Surgical Research 23:141-148
✓	AJJ	Donahoe et al (1981) "Mullerian Inhibiting Substance Inhibits Growth of a Human Ovarian Cancer in Nude Mice" Annual Meeting of the American Surgical Association, Chicago, Illinois, April 22-24, 1991, 472-M.

Examiner Signature <i>Misook Y</i>	Date Considered 11-10-2003
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449
(Modified)U.S. Department of Commerce
Patent and Trademark OfficeAttorney's Docket No.
10287-051001Application No.
09/536,087**Information Disclosure Statement
by Applicant**

(Use several sheets if necessary)

(37 CFR §1.98(b))

Applicant
Michael J. Detmar et al.Filing Date
March 24, 2000Group Art Unit
1642MAR 12 2003
TECH CENTER 1600/2980

RECEIVED

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
my	AKK	Fuller et al. (1998) "Mufkrim Io6tbimej Substance Reduction of Colony Growth of Hum Gynecologic Cancers in a Stan Cell Amy" Gynecologic Oncology 22:135-148
	ALL	Fingert et al. (1987) "Rapd growth of lumen cancer cells o a mouse model with Fibrin Clot Subrmal C ask Amy" Caroer Research 4738243829.
	AMM	Gustafson, M (1992) "Mullerian luhbiting Substance as a marker for Ovarian sex-cord turnor," The New England Jorlnl of Medicine. vol. 326(7):46& 471.
	ANN	Fuller et al., (1982) "Mullerian irdnbting Substance Inhibits Colony Growth of a Hmnan Ovarian Carcinoma Cell Line" Journal of Clinical Endocrinology and Metabolism vol. 54(5): 1051-1055
	AOO	Hudson et al., (1990) "An Iummonsay to Detect Human Mulkrian Inhibiting Substance in Males and Females during Normal Development" Journal of Clinical Endocrinology and Metabolism, vol. 70(1). 16-22
	APP	Kurian et al. (1995) "Cleavage of MuSaem Inhibiting Substance Activates Antiproliferative Effeeta m Vivo" vol. 1, 343-349
	AQQ	Lee, M et al. (19%) "Mullerian Inhibiting substance in human: Normal Levels from Infancy' to Adulthood" Journal ofClinical Endocrinology and Metabolism, vol. 81(2)571-576
	ARR	Masiakos et al. (1999) "Hunan Ovarian Cancer, Cell lines, and primary ascites Cells Express the Hunan Mullerian Inhibiting Substance (MIS) Type II Receptor, Bind, and are responsive to MIS" Clinical Cancer Research, vol. 5, 3488-3499
	ASS	MacLaughlin or al. (1991) "Bioamy, Purificatioq Cloning and Expression of Mullerian Inlnbit6ig Substance" Methods m Enzymology, vol. 198: 358-369
	ATT	MacLaughlin et al (1992) "Mullerian Duct Regression and Antipmlifaative Bioaaivities of Mulerian InMbting Substance Reside in its Canboxy-Tetnmal Domain" Endocrinology, vol 131(1):291-2%
	AUU	O' Relly et al. (1999) "AMianpogaoc Activity of die Cleaved Conformation of the Serpm Antidmombm" Science, vol. 285:1926-1929
	AVV	Pepinsky, R, (1988) "Proteoly6c pmcessingofMullaian Inhibiting Substance produces a transforming growth factor-B-Irlte Fragment" The Journal of Biological Chemistry, vol. 263(35): 18%1-18964
	AWW	Parry et al. (1992) "Recombinant Hunan Mulerian Inhibiting Sustance Inhibits Hunan Ocular Melanoma Cell Lines in vitro and in vivo" Cancer Research, vol. 52:1182-1186
	AXX	Ragin, R., (1992) "Huron Mullerian Inhibiting Substance: Enhanced Purification Inputs Biochemical Stability and Restores Antipro6ferative Effects" Protein Expression and Purification 3: 236-245
	YYY	Teixeira J. and Donahoe, P., (1996) "Molecular Biology of MIS and Its Receptors" Journal of Andrology, vol. 17(4): 336-341
	AZZ	Teixeira, J. et al. (19%) "Developmental Expression of & Candidate Mulkrian Inhibiting Substance Type 11 Receptor. Endocrinology, vol. 137(1): 160-165
	AAAA	Teixeira, J. (1999) "Transcriptional regulation of the Tat Millerian inhibiting substance type 11 receptor in rodent LeAig cells" PNAS, vol. 96(24) 13831 13838
	ABBB	Chamberlain. et al. Bamaterials(1998) 19:1393-1403.
	ACCC	Hadlock et al. Laryngoscope (1999) 109(9):1412-1416.

Examiner Signature

Date Considered

11-10-2003


EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

OIPE JC17
 MAR 10 2003
 PATENT & TRADEMARK OFFICE

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10287-051001	Application No. 09/536,087
	Applicant Michael J. Detmar et al.		
	Filing Date March 24, 2000	Group Art Unit 1642	

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
my	ADDD	Kristjansen, P.E. et al. Microvesc. Res. 48, 389402 (1994)
	AEEE	Matsuda a al. ASAIO, 38: 154-157 (1992)
	AFFF	Wells a al., Exp. NeaoL (1997)146(2r 395402
	AGGG	Woerly et al., (1999) J. Tits- Engineering 5(S): 467488
	AHHH	Anderson W.F., Hunan gene therapy. <u>Nature</u> 392 (6679 Suppl.~ 25-30 (1998)
	AIII	Berger, A.C. et &L, J. Surg. Res. 91, 26-31 (2000)
	AJJJ	Boehm, T., a al. Nature 390,404-407 (1997)
	AKKK	Crystal, R.G. Nat Biotechnol 17,336-337 (1999)
	ALLL	Carmeliet, D. et al. Name 407, 249-257 (2000)
	AMMM	Christofori, Angiogenesis 1998, 2:21-23
	ANNN	Despont, a al., "High-Aspect-Ratio, Ulaathick, Negative-Tone Near-UV Photoresist for MEMS," Proc. of IEEE 10" Annual International Workshop on MEMS, Nagoya, Japan, pp S 18-522 (Jan 26-30,1997)
	AOOO	Drixler, T.A. et &L, Cancer Res. 60,1761-1765 (2000)
	APPP	Feldman, A.L et al. Cancer 99, 1191-1194 (2000)
	AQQQ	Hahnfeldt, P., ct al. Cancer Res. 59, 47704775 (1999)
	ARRR	Kerbel, RS. Carcinogenesis 21: 505-515(2000)
	ASSS	Kaufman (1987) EMBO J. 6:187-195
	ATTT	Lawler, J. Curr. Opin. Cell Biol. 12, 634-640 (2000)
	AUUU	Murphy-Ullrich et al., Biol. Chem 268, 26784-26789 (1993)
	AVVV	Pros. SPIE-Imanationd Soc. Optical Engineer. 2879,156-167 (1996)
	AWWW	Pike, S.E. et al. J. Exp. Med. 188, 2349-2356 (1998)
	AXXX	Streit et. al, Proc Natl Acad Sci USA 96(26): 14888-14893 (1999)
	AYYY	Schift et al. "Fabrication of replicated high precision insert elements for micro-optical bench arrangements" Proc. SPIE- International Soc. Optical Engineer. 3513.122-134 (1998)
	AZZZ	Sachs et. al., "CAD-Casting: Dined Fabrication ofCerauicc Shells and Cores by Throe Dbnensioml Printing° Maenfadrng Review 5(2),117-126 (1992)
	AAAAA	Seed (1987) Nature 329: 840
✓	ABBBB	Chertington, et al. (2000) "New Paradigms for the Treatment of Cancer: The Role of Anti-angiogenesis agents" Adv. Cancer Res. 79:1-38. (abstract)

Examiner Signature <i>msm</i>	Date Considered 11-10-03
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10287-051001	Application No. 09/536,087
	Applicant Michael J. Detmar et al.		
	Filing Date March 24, 2000	Group Art Unit 1642	

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
my	ACCCC	Kirsch et al. (2001) "Therapeutic Anti-Angiogenesis for Malignant Brain Tumors" Onkologie 24:423-430
	ADDDD	Hagedorn a al. (2000) "Critical Reviews in Oncology/Hanatology 34:89-110
	AEEEE	Carpizo and Arispe, (2000) "Cancer and Metastasis Reviews" 19:159-165
	AFFFF	Locopo, et al., 1998, breast Cancer Res Treat, 52:159-173
	AGGGG	Vacanti, et al., 1988, J Pediatr surg, 23(1 Pt 2):3-9
	AHHHH	Streit, et al., 1999, Am. J of Pathology, 155(2):441-452

MAR 12 2003
EX-160012800
MED

Examiner Signature <i>Misook</i>	Date Considered 11-10-03
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	